(Reuters) - As a result of the FDA's decision, the company said it may have to make significant infrastructure and staff cuts in the United States. It is also reviewing its strategic alternatives.
According to Houston-based Encysive, the U.S. Food and Drug Administration , in a third approvable letter, said Thelin did not demonstrate the effectiveness required for approval as a treatment for pulmonary arterial hypertension, or PAH.
Read more at Reuters.com Hot Stocks News
According to Houston-based Encysive, the U.S. Food and Drug Administration , in a third approvable letter, said Thelin did not demonstrate the effectiveness required for approval as a treatment for pulmonary arterial hypertension, or PAH.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment